Today, health research has high value to society. It provides important information about disease trends and risk factors, outcomes of treatment or public health interventions, functional abilities, patterns of care, and health care costs and use. Although medical researchers have determined the causes of serious disorders and genetic ailments through symptoms and morphology they have failed to bore the root cause of ailments. Today, every medical operation generates huge amount of data but understanding the meaning of that data can be more of a challenge. Understanding this challenge in the healthcare, many intuitive vendors have come forth to give advantage to healthcare researchers by translating raw genomic data into meaningful scientific insights. Bangalore based InterpretOmics makes use of genomic data to develop tools and solutions that can address the complexities of Genomics data and drive actionable insights to Biotech’s, Pharma companies and Agriculture firms with unprecedented ease and accuracy. “We completely understand the importance of computing, statistics and mathematics in Biology which is why we are able to master the art of genomic data sciences,” says Prahalad Achutharao, Founder & CEO at InterpretOmics. Harnessing the power of data science and translating it into Life science, the company has bent its vision towards analyzing, and interpreting data to derive meaningful insights, thereby aiding pharmaceutical companies in biomarker and drug target discovery.

Being India’s first Data Sciences company pioneering data driven science for solving the big data challenges in Health Sciences, Agriculture and BioEnergy, InterpretOmics credits its flagship product: iOMICS™ , which is a cloud-based software platform for aggregating and structuring genomics and biomedical data.

Specifically designed for researchers in Biotech’s, Pharmaceutical companies, and agriculture firms, iOMICS™ usage is quite simple. “The software encompasses the knowledge and expertise of computer scientists, mathematicians, Bioinformaticians and statisticians. It is as good as having human experts from these respective domains analyzing the genomic data for you”, says Prahalad. It recently expanded its offering from being just a genomics data analysis company to an end-to-end sequencing and interpretation services company with the addition of its new state of the art Center for Next Generation Sequencing in Bangalore. The company has geared up to support healthcare organizations and diagnostic companies focused on precision care, which calls to decipher some or all of a person’s genome. “President Obama’s announcement of a Precision Medicine Initiative was one of the few items in this year’s State of the Union address. Through this initiative, President Obama has long expressed a strong conviction that science offers great potential for improving health. And we have aligned ourselves to this initiative with our suite of genomics oriented products such as iOMICS, DiscoverX and HLAScape for generating rapid and accurate decisions and eventually helping physicians take medical decisions to improve the life and disease conditions of their patients,” adds Prahalad.

The next generation market of genomics is slated to be around $1.6 trillion and with InterpretOmics’ On-premise and Cloud offerings, the growth opportunities are tremendous in this market. With a strong client base including US-based Joint Genome Institute, Indian Council of Agricultural Research, All India Institute of Medical Sciences (AIIMS) and Biocon, the company wants to continue tapping the huge opportunities of Big [Genomics] Data market and create new discoveries in the field of disease management, crop management and energy management.